<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_GPB672 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEgr3 jpg ?>
<?FILEmmc1 xlsx ?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Genomics Proteomics Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Genomics Proteomics Bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>Genomics, Proteomics &amp; Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1672-0229</issn>
    <issn pub-type="epub">2210-3244</issn>
    <publisher>
      <publisher-name>Elsevier</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10626054</article-id>
    <article-id pub-id-type="pii">S1672-0229(22)00128-0</article-id>
    <article-id pub-id-type="doi">10.1016/j.gpb.2022.09.012</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Database</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>TSNAdb v2.0: The Updated Version of Tumor-specific Neoantigen Database</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au005">
        <name>
          <surname>Wu</surname>
          <given-names>Jingcheng</given-names>
        </name>
        <xref rid="af005" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au010">
        <name>
          <surname>Chen</surname>
          <given-names>Wenfan</given-names>
        </name>
        <xref rid="af005" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au015">
        <name>
          <surname>Zhou</surname>
          <given-names>Yuxuan</given-names>
        </name>
        <xref rid="af005" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au020">
        <name>
          <surname>Chi</surname>
          <given-names>Ying</given-names>
        </name>
        <xref rid="af010" ref-type="aff">2</xref>
      </contrib>
      <contrib contrib-type="author" id="au025">
        <name>
          <surname>Hua</surname>
          <given-names>Xiansheng</given-names>
        </name>
        <xref rid="af010" ref-type="aff">2</xref>
      </contrib>
      <contrib contrib-type="author" id="au030">
        <name>
          <surname>Wu</surname>
          <given-names>Jian</given-names>
        </name>
        <xref rid="af015" ref-type="aff">3</xref>
        <xref rid="af020" ref-type="aff">4</xref>
      </contrib>
      <contrib contrib-type="author" id="au035">
        <name>
          <surname>Gu</surname>
          <given-names>Xun</given-names>
        </name>
        <xref rid="af025" ref-type="aff">5</xref>
      </contrib>
      <contrib contrib-type="author" id="au040">
        <name>
          <surname>Chen</surname>
          <given-names>Shuqing</given-names>
        </name>
        <xref rid="af005" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au045">
        <name>
          <surname>Zhou</surname>
          <given-names>Zhan</given-names>
        </name>
        <email>zhanzhou@zju.edu.cn</email>
        <xref rid="af005" ref-type="aff">1</xref>
        <xref rid="af010" ref-type="aff">2</xref>
        <xref rid="af020" ref-type="aff">4</xref>
        <xref rid="cor1" ref-type="corresp">⁎</xref>
      </contrib>
      <aff id="af005"><label>1</label>Institute of Drug Metabolism and Pharmaceutical Analysis and Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China</aff>
      <aff id="af010"><label>2</label>Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Alibaba DAMO Academy, Hangzhou 311121, China</aff>
      <aff id="af015"><label>3</label>The Second Affiliated Hospital of School of Medicine, and School of Public Health, Zhejiang University, Hangzhou 310058, China</aff>
      <aff id="af020"><label>4</label>Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou 310018, China</aff>
      <aff id="af025"><label>5</label>Department of Genetics, Development and Cell Biology, Iowa State University, Ames, IA 50011, USA</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>⁎</label>Corresponding author. <email>zhanzhou@zju.edu.cn</email></corresp>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>06</day>
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="ppub">
      <month>4</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>06</day>
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <volume>21</volume>
    <issue>2</issue>
    <fpage>259</fpage>
    <lpage>266</lpage>
    <history>
      <date date-type="received">
        <day>27</day>
        <month>3</month>
        <year>2022</year>
      </date>
      <date date-type="rev-recd">
        <day>24</day>
        <month>9</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>30</day>
        <month>9</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 The Authors</copyright-statement>
      <copyright-year>2023</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
      </license>
    </permissions>
    <abstract id="ab005">
      <p>In recent years, <bold>neoantigens</bold> have been recognized as ideal targets for <bold>tumor immunotherapy</bold>. With the development of neoantigen-based tumor immunotherapy, comprehensive neoantigen <bold>databases</bold> are urgently needed to meet the growing demand for clinical studies. We have built the tumor-specific neoantigen database (TSNAdb) previously, which has attracted much attention. In this study, we provide TSNAdb v2.0, an updated version of the TSNAdb. TSNAdb v2.0 offers several new features, including (1) adopting more stringent criteria for neoantigen identification, (2) providing predicted neoantigens derived from three types of <bold>somatic mutations</bold>, and (3) collecting experimentally validated neoantigens and dividing them according to the experimental level. TSNAdb v2.0 is freely available at <ext-link ext-link-type="uri" xlink:href="https://pgx.zju.edu.cn/tsnadb/" id="ir005">https://pgx.zju.edu.cn/tsnadb/</ext-link>.</p>
    </abstract>
    <kwd-group id="kg005">
      <title>Keywords</title>
      <kwd>Neoantigen</kwd>
      <kwd>Tumor immunotherapy</kwd>
      <kwd>Human leukocyte antigen</kwd>
      <kwd>Somatic mutation</kwd>
      <kwd>Database</kwd>
    </kwd-group>
  </article-meta>
  <notes>
    <p id="ms005">Handled by Yu Xue</p>
  </notes>
</front>
<body>
  <sec id="s0005">
    <title>Introduction</title>
    <p id="p0005">Tumor neoantigens are tumor-specific antigens derived from somatic mutations in tumor cells, which have been recognized as ideal targets for tumor immunotherapy in recent years <xref rid="b0005" ref-type="bibr">[1]</xref>, <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>. Due to the huge workload for experimental verification, it is preferred to utilize cancer genomics and bioinformatics for neoantigen identification. Numerous prediction tools considering the biological process of neoantigen generation, such as human leukocyte antigen (HLA)–peptide binding <xref rid="b0025" ref-type="bibr">[5]</xref>, <xref rid="b0030" ref-type="bibr">[6]</xref>, <xref rid="b0035" ref-type="bibr">[7]</xref>, have been developed, which have been embedded in neoantigen prediction pipelines such as pVACtools <xref rid="b0040" ref-type="bibr">[8]</xref>, tumor-specific neoantigen detector (TSNAD) <xref rid="b0045" ref-type="bibr">[9]</xref>, <xref rid="b0050" ref-type="bibr">[10]</xref>, and pTuneos <xref rid="b0055" ref-type="bibr">[11]</xref>. Neoantigen-related databases such as TRON cell line portal (TCLP) <xref rid="b0060" ref-type="bibr">[12]</xref>, the cancer immunome atlas (TCIA) <xref rid="b0065" ref-type="bibr">[13]</xref>, and tumor-specific neoantigen database (TSNAdb) <xref rid="b0070" ref-type="bibr">[14]</xref> have also been created for better usage of neoantigens in clinical research. In TSNAdb v1.0, we took the complex of mutated peptides and HLA class I molecules (peptide–HLA pairs, pHLAs) as tumor neoantigens and predicted binding affinities between mutated/wild-type pHLAs by NetMHCpan v2.8/v4.0. We then obtained 3,707,562/1,146,961 potential neoantigens derived from single nucleotide variants (SNVs) of 7748 tumor samples from The Cancer Genome Atlas (TCGA, <ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/" id="ir010">https://portal.gdc.cancer.gov/</ext-link>). With the development of neoantigen-based tumor immunotherapy, neoantigens from other types of mutations have been identified, and more experimental data have been generated <xref rid="b0075" ref-type="bibr">[15]</xref>, <xref rid="b0080" ref-type="bibr">[16]</xref>. Therefore, it is urgent to perform system updates for the TSNAdb v1.0.</p>
    <p id="p0010">Here, we present an updated version of TSNAdb v1.0 that improves on the following points. (1) More stringent criteria were used for neoantigen identification to reduce the high false-positive rate of neoantigen prediction in practice. Only the pHLAs that met the thresholds of three tools were considered potential neoantigens (<xref rid="f0005" ref-type="fig">Figure 1</xref>). The pHLAs would not be considered neoantigens if the mutated genes were not expressed in the tumor cells. (2) We provided predicted neoantigens derived not only from SNVs but also from insertions/deletions (INDELs) and gene fusions (Fusions). In total, 372,273 SNV-derived neoantigens, 137,130 INDEL-derived neoantigens, and 11,093 Fusion-derived neoantigens were obtained. The mean number of neoantigens generated for each SNV (0.38) was lower than each INDEL (1.22) or Fusion (0.88). (3) We collected as many experimentally validated neoantigens from public databases and literature as possible (1856 neoantigens) and divided them into three tiers according to the level of experimental verification. Corresponding genes and mutations of the collected neoantigens were linked to the cancer-driving site profiling database (CandrisDB) <xref rid="b0085" ref-type="bibr">[17]</xref> since neoantigens derived from driver genes or driver mutations would be ideal targets for tumor immunotherapy <xref rid="b0090" ref-type="bibr">[18]</xref>.<fig id="f0005"><label>Figure 1</label><caption><p><bold>The neoantigen prediction process of TSNAdb v2.0</bold></p><p>SNV, single nucleotide variant; INDEL, insertion/deletion; Fusion, gene fusion; HLA, human leukocyte antigen; TPM, transcripts per million reads.</p></caption><graphic xlink:href="gr1"/></fig></p>
    <p id="p0015">We believe that the updated database will contribute to neoantigen-based tumor immunotherapy and that the database will continue updating in the aspect of predicting neoantigens from more types of mutations and collecting more experimentally validated neoantigens.</p>
  </sec>
  <sec id="s0010">
    <title>Database content and usage</title>
    <sec id="s0015">
      <title>Data collection and preprocessing</title>
      <p id="p0020">The SNVs, INDELs, and the expression level of corresponding genes were collected from TCGA. Mutated nucleotide sequences generated by SNVs and INDELs are translated into mutated amino acid sequences and have been decomposed into 8 to 11 peptides using the pipeline TSNAD v2.0 <xref rid="b0050" ref-type="bibr">[10]</xref>. The Fusions were collected from Gao et al. <xref rid="b0095" ref-type="bibr">[19]</xref>, and the mutated proteins were generated by STAR-Fusion <xref rid="b0100" ref-type="bibr">[20]</xref>. The HLA alleles of corresponding samples were collected from TCIA. Finally, 972,187 SNVs from 7748 samples, 112,404 INDELs from 7086 samples, and 12,639 Fusions from 4234 samples were used for neoantigen prediction.</p>
    </sec>
    <sec id="s0020">
      <title>Stricter criteria for neoantigen identification</title>
      <p id="p0025">Neoantigen-based tumor immunotherapy has shown good application prospects in clinical practice. However, the high false-positive rate of neoantigen prediction limits its usage. How to select high-confidence immunogenic neoantigens remains to be resolved. To reduce the potential false-positive rate in our predicted results, three tools (DeepHLApan, MHCflurry, and NetMHCpan v4.0) were used for neoantigen prediction, and only the pHLAs that met all the criteria of the three tools were considered potential neoantigens (<xref rid="f0005" ref-type="fig">Figure 1</xref>). The reason we chose these three tools is as follows: NetMHCpan <xref rid="b0035" ref-type="bibr">[7]</xref> is the most frequently used tool for neoantigen prediction in clinical practice. MHCflurry <xref rid="b0030" ref-type="bibr">[6]</xref> obtains the prediction neoantigen efficiently and with high quality. DeepHLApan <xref rid="b0025" ref-type="bibr">[5]</xref> considers both HLA-peptide binding and immunogenicity of pHLA that the other two tools have not taken into consideration for high-confidence neoantigen prediction. The threshold of each tool is as follows. For NetMHCpan v4.0, pHLA with rank &lt; 2% or affinity &lt; 500 nM is considered binding, and we used both thresholds to select higher quality neoantigens. The output of MHCflurry is rank % and has no specific threshold. We set rank &lt; 2% as the threshold, which is the same as NetMHCpan v4.0. The predicted scores of DeepHLApan are posterior probabilities, so we set the threshold to 0.5. In addition, the pHLAs whose corresponding genes were not expressed [transcripts per million reads (TPM) &lt; 1] were removed.</p>
    </sec>
    <sec id="s0025">
      <title>Neoantigens derived from three types of mutation</title>
      <p id="p0030">Neoantigens are not only generated from SNVs but also generated from other mutations, such as INDELs and Fusions. Based on the analysis of different types of mutations in TCGA tumor samples, we provided 137,130 INDEL-derived neoantigens and 11,093 Fusion-derived neoantigens into TSNAdb v2.0. The number of predicted neoantigens derived from SNVs was greater than that derived from INDELs and Fusions due to the greatest number of SNVs among the somatic mutations collected. However, the average number of neoantigens derived from each SNV (0.38) was less than that derived from each INDEL (1.22) or each Fusion (0.88) (<xref rid="t0005" ref-type="table">Table 1</xref>). We further explored the relationship between the number of mutations and neoantigens for the three mutation types. The results showed that the numbers of SNV-derived neoantigens and INDEL-derived neoantigens had positive correlations with the numbers of SNVs and INDELs, with the Pearson correlation coefficient <italic>r</italic> = 0.925 and <italic>r</italic> = 0.902, respectively (<xref rid="f0010" ref-type="fig">Figure 2</xref>A and B). There was no significant correlation between the number of Fusion-derived neoantigens and the number of Fusions (<xref rid="f0010" ref-type="fig">Figure 2</xref>C, <italic>r</italic> = 0.452), which might be attributed to the fact that the number of neopeptides each Fusion generated varies greatly.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>The distribution of mutations and neoantigens across 16 tumor types</p></caption><table frame="hsides" rules="groups"><thead><tr><th><bold>Mutation type</bold></th><th><bold>Tissue</bold></th><th><bold>No. of samples</bold></th><th><bold>No. of mutations</bold></th><th><bold>No. of neoantigens</bold></th><th><bold>No. of neoantigens per mutation</bold></th></tr></thead><tbody><tr><td rowspan="16">SNV</td><td>Bladder</td><td>408</td><td>74,707</td><td>21,070</td><td rowspan="16">0.38</td></tr><tr><td>Brain</td><td>151</td><td>16,197</td><td>5227</td></tr><tr><td>Breast</td><td>982</td><td>62,211</td><td>18,238</td></tr><tr><td>Cervix</td><td>286</td><td>46,607</td><td>11,906</td></tr><tr><td>Colorectal</td><td>531</td><td>165,293</td><td>39,116</td></tr><tr><td>Head and neck</td><td>495</td><td>55,968</td><td>13,728</td></tr><tr><td>Kidney</td><td>681</td><td>26,170</td><td>8499</td></tr><tr><td>Liver</td><td>358</td><td>28,024</td><td>5987</td></tr><tr><td>Lung</td><td>999</td><td>212,861</td><td>52,801</td></tr><tr><td>Ovary</td><td>305</td><td>28,478</td><td>7631</td></tr><tr><td>Pancreas</td><td>166</td><td>17,221</td><td>3985</td></tr><tr><td>Prostate</td><td>493</td><td>16,424</td><td>5363</td></tr><tr><td>Skin</td><td>466</td><td>206,907</td><td>43,882</td></tr><tr><td>Stomach</td><td>411</td><td>103,103</td><td>24,497</td></tr><tr><td>Thyroid</td><td>488</td><td>4425</td><td>1218</td></tr><tr><td>Uterus</td><td>528</td><td>415,499</td><td>109,125</td></tr><tr><td colspan="6">  </td></tr><tr><td rowspan="16">INDEL</td><td>Bladder</td><td>389</td><td>2890</td><td>3532</td><td rowspan="16">1.22</td></tr><tr><td>Brain</td><td>130</td><td>366</td><td>375</td></tr><tr><td>Breast</td><td>888</td><td>5207</td><td>6123</td></tr><tr><td>Cervix</td><td>257</td><td>3095</td><td>4234</td></tr><tr><td>Colorectal</td><td>520</td><td>21,327</td><td>29,876</td></tr><tr><td>Head and neck</td><td>478</td><td>3569</td><td>4913</td></tr><tr><td>Kidney</td><td>648</td><td>5318</td><td>6395</td></tr><tr><td>Liver</td><td>353</td><td>2120</td><td>2143</td></tr><tr><td>Lung</td><td>983</td><td>10,790</td><td>12,407</td></tr><tr><td>Ovary</td><td>296</td><td>4260</td><td>4441</td></tr><tr><td>Pancreas</td><td>141</td><td>457</td><td>806</td></tr><tr><td>Prostate</td><td>416</td><td>1448</td><td>2119</td></tr><tr><td>Skin</td><td>430</td><td>1965</td><td>2557</td></tr><tr><td>Stomach</td><td>393</td><td>19,912</td><td>24,838</td></tr><tr><td>Thyroid</td><td>248</td><td>1746</td><td>1657</td></tr><tr><td>Uterus</td><td>516</td><td>27,934</td><td>30,714</td></tr><tr><td colspan="6">  </td></tr><tr><td rowspan="16">Fusion</td><td>Bladder</td><td>269</td><td>809</td><td>819</td><td rowspan="16">0.88</td></tr><tr><td>Brain</td><td>92</td><td>244</td><td>245</td></tr><tr><td>Breast</td><td>787</td><td>3390</td><td>3457</td></tr><tr><td>Cervix</td><td>139</td><td>280</td><td>215</td></tr><tr><td>Colorectal</td><td>167</td><td>328</td><td>231</td></tr><tr><td>Head and neck</td><td>285</td><td>532</td><td>530</td></tr><tr><td>Kidney</td><td>171</td><td>318</td><td>420</td></tr><tr><td>Liver</td><td>179</td><td>513</td><td>423</td></tr><tr><td>Lung</td><td>716</td><td>1992</td><td>710</td></tr><tr><td>Ovary</td><td>316</td><td>983</td><td>609</td></tr><tr><td>Pancreas</td><td>72</td><td>130</td><td>161</td></tr><tr><td>Prostate</td><td>381</td><td>1079</td><td>1120</td></tr><tr><td>Skin</td><td>287</td><td>841</td><td>918</td></tr><tr><td>Stomach</td><td>178</td><td>559</td><td>486</td></tr><tr><td>Thyroid</td><td>110</td><td>140</td><td>250</td></tr><tr><td>Uterus</td><td>85</td><td>501</td><td>499</td></tr></tbody></table><table-wrap-foot><fn><p><italic>Note</italic>: SNV, single nucleotide variant; INDEL, insertion/deletion; Fusion, gene fusion.</p></fn></table-wrap-foot></table-wrap><fig id="f0010"><label>Figure 2</label><caption><p><bold>The relationship between the number of mutations and the number of neoantigens across 16 tumor types of three mutation types</bold></p><p><bold>A.</bold> The relationship between the number of SNVs and SNV-derived neoantigens. <bold>B.</bold> The relationship between the number of INDELs and INDEL-derived neoantigens. <bold>C.</bold> The relationship between the number of Fusions and Fusion-derived neoantigens. The Pearson correlation coefficient is used for evaluation.</p></caption><graphic xlink:href="gr2"/></fig></p>
    </sec>
    <sec id="s0030">
      <title>Shared neoantigens generated from frequent somatic mutations</title>
      <p id="p0035">Currently, most neoantigen-targeted immunotherapies are personalized and expensive, which led us to wonder if we could identify shared neoantigens that can be applied to a wider range of tumor patients. Here, we analyzed the frequency of each neoantigen and obtained 16,913 neoantigens shared in at least two tumor samples (<xref rid="s0070" ref-type="sec">Table S1</xref>). Among three SNV-derived neoantigens shared in more than 20 samples, the mutated peptides are generated from <italic>BRAF</italic> and <italic>KRAS</italic>, which are well-known cancer driver genes. The most frequent shared neoantigen derived from SNV is the complex of HLA-B57:01 and mutated peptide GLAT<italic><underline>E</underline></italic>KSRW generated by <italic>BRAF</italic> V600E, which is present in 41 tumor samples. The complex of HLA-A02:01 and the neopeptides RLMAPVGSV and SLLTQPSPA generated by the frameshift mutation <italic>XYLT2</italic> G529Afs*78 are the most frequent neoantigens among INDEL-derived neoantigens, which both appear in 31 samples (<xref rid="t0010" ref-type="table">Table 2</xref>). The two Fusion-derived shared neoantigens are the complex of HLA-A02:01 and the neopeptides ALNS<italic><underline>EALSVV</underline></italic> and ALNS<italic><underline>EALSV</underline></italic> generated by the fusion of the <italic>TMPRSS2</italic> and <italic>ERG</italic> genes<italic>,</italic> which both appear in 14 samples (<xref rid="s0070" ref-type="sec">Table S1</xref>). We believe that these shared neoantigens are expected to be ideal drug targets for tumor immunotherapy, which might need further experimental validation.<table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>The detailed information of shared neoantigens present in more than 20 samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th><bold>Mutation type</bold></th><th><bold>Gene</bold></th><th><bold>Mutation</bold></th><th><bold>HLA</bold></th><th><bold>Peptide</bold></th><th><bold>No. of samples</bold></th></tr></thead><tbody><tr><td>SNV</td><td><italic>BRAF</italic></td><td>V600E</td><td>HLA-B57:01</td><td>GLATEKSRW</td><td>41</td></tr><tr><td>SNV</td><td><italic>KRAS</italic></td><td>G12D</td><td>HLA-B08:01</td><td>DGVGKSAL</td><td>37</td></tr><tr><td>INDEL</td><td><italic>XYLT2</italic></td><td>G529Afs*78</td><td>HLA-A02:01</td><td>RLMAPVGSV</td><td>31</td></tr><tr><td>INDEL</td><td><italic>XYLT2</italic></td><td>G529Afs*78</td><td>HLA-A02:01</td><td>SLLTQPSPA</td><td>31</td></tr><tr><td>SNV</td><td><italic>KRAS</italic></td><td>G12V</td><td>HLA-A03:01</td><td>VVGAVGVGK</td><td>30</td></tr><tr><td>INDEL</td><td><italic>SETD1B</italic></td><td>H8Tfs*27</td><td>HLA-C07:01</td><td>LRARGGTTI</td><td>29</td></tr><tr><td>INDEL</td><td><italic>PLEKHA6</italic></td><td>V328Yfs*172</td><td>HLA-A02:01</td><td>IMMSWMPPL</td><td>25</td></tr><tr><td>INDEL</td><td><italic>PLEKHA6</italic></td><td>V328Yfs*172</td><td>HLA-A02:01</td><td>VLSGCHLAV</td><td>25</td></tr><tr><td>INDEL</td><td><italic>XYLT2</italic></td><td>G529Afs*78</td><td>HLA-C07:02</td><td>GRTPTTRLM</td><td>25</td></tr><tr><td>INDEL</td><td><italic>PLEKHA6</italic></td><td>V328Yfs*172</td><td>HLA-A02:01</td><td>FTPLSAHPV</td><td>25</td></tr><tr><td>INDEL</td><td><italic>PLEKHA6</italic></td><td>V328Yfs*172</td><td>HLA-A02:01</td><td>CLAGSLSTM</td><td>25</td></tr><tr><td>INDEL</td><td><italic>PLEKHA6</italic></td><td>V328Yfs*172</td><td>HLA-A02:01</td><td>SAMPSAMGV</td><td>25</td></tr><tr><td>INDEL</td><td><italic>PLEKHA6</italic></td><td>V328Yfs*172</td><td>HLA-A02:01</td><td>SIMMSWMPPL</td><td>25</td></tr><tr><td>INDEL</td><td><italic>XYLT2</italic></td><td>G529Afs*78</td><td>HLA-B07:02</td><td>RPACTCISM</td><td>23</td></tr><tr><td>INDEL</td><td><italic>XYLT2</italic></td><td>G529Afs*78</td><td>HLA-B07:02</td><td>HPQWAPHSA</td><td>23</td></tr><tr><td>INDEL</td><td><italic>XYLT2</italic></td><td>G529Afs*78</td><td>HLA-B07:02</td><td>RPTGRTPTTRL</td><td>23</td></tr><tr><td>INDEL</td><td><italic>XYLT2</italic></td><td>G529Afs*78</td><td>HLA-B07:02</td><td>SPGACRPAC</td><td>23</td></tr><tr><td>INDEL</td><td><italic>XYLT2</italic></td><td>G529Afs*78</td><td>HLA-B07:02</td><td>RPTGRTPTT</td><td>23</td></tr><tr><td>INDEL</td><td><italic>MUC4</italic></td><td>L1937Pfs*1069</td><td>HLA-B07:02</td><td>HPQVTPPL</td><td>23</td></tr><tr><td>INDEL</td><td><italic>MUC4</italic></td><td>L1937Pfs*1069</td><td>HLA-B07:02</td><td>HPQVTPPLF</td><td>23</td></tr><tr><td>INDEL</td><td><italic>SETD1B</italic></td><td>H8Tfs*27</td><td>HLA-C07:02</td><td>LRARGGTTI</td><td>22</td></tr><tr><td>INDEL</td><td><italic>MUC4</italic></td><td>L1937Pfs*1069</td><td>HLA-B07:02</td><td>LPQHPQVTPPL</td><td>21</td></tr></tbody></table><table-wrap-foot><fn><p><italic>Note</italic>: fs*78 indicates that 78 amino acids have been changed after the frameshift site. HLA, human leukocyte antigen; fs, frameshift.</p></fn></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="s0035">
      <title>Experimentally validated neoantigens</title>
      <p id="p0040">On the “Validation” page of TSNAdb v1.0, we only collected experimental data about wild-type pHLAs that were difficult to identify as neoantigens due to the limited binding data between mutated pHLAs. With the development of clinical studies on neoantigen-based tumor immunotherapy, a large number of experimental results have provided a rich source for the functional confirmation of neoantigens. Here, we collected experimentally validated mutated pHLAs not only from several neoantigen databases (dbPepNeo <xref rid="b0105" ref-type="bibr">[21]</xref>, NeoPeptide <xref rid="b0110" ref-type="bibr">[22]</xref>, NEPdb <xref rid="b0115" ref-type="bibr">[23]</xref>, and Cancer Antigenic Peptide Database <xref rid="b0120" ref-type="bibr">[24]</xref>) but also from published literature through data mining. For the neoantigens without gene or mutation information, BLAST was used to determine the mutated genes and the positions of somatic mutations at proteins. All collected data were further checked to determine whether the neoantigens were immunogenic or presented to the cell surface, and the collected neoantigens were divided into three tiers according to the experimental level. Neoantigens that have been both validated as immunogenic and to be presented to the cell surface were labeled tier 1, while those only validated as immunogenic were labeled tier 2, and those only validated to be presented to the cell surface were labeled tier 3. We collected 1856 experimental neoantigens, among which 67 neoantigens were classified as tier 1, 1190 neoantigens were classified as tier 2, and 599 neoantigens were classified as tier 3. Among the collected neoantigens, most were SNV-derived (22 were Fusion-derived, 125 were INDEL-derived, 23 were noncoding-derived, 33 were RNA splice-derived, and the remaining were SNV-derived) and enriched in several tumor types (430 belonged to lung cancer, 477 belonged to skin cancer, 361 belonged to B-cell lymphoma, and 123 belonged to colorectal cancer).</p>
    </sec>
    <sec id="s0040">
      <title>The usage of TSNAdb v2.0</title>
      <p id="p0045">The web interface of TSNAdb v2.0 contains seven pages: “Home”, “Browse”, “Search”, “Collected”, “Tools”, “Download”, and “Help”. The pages “Home”, “Download”, and “Help” are similar to those presented in TSNAdb v1.0. The “Tools” page is newly added to provide the links of DeepHLApan and TSNAD, which we developed previously for neoantigen prediction. Major changes (such as more presentation forms, more correlation analysis, and more meaningful links) have been made in the pages “Browse”, “Search”, and “Collected” compared to the TSNAdb v1.0.</p>
      <p id="p0050">On the “Browse” page, three subpages (“Mutation type”, “Tumor type”, and “Shared neoantigens”) are provided for customized neoantigen browsing. In “Mutation type”, four parts, “Statistics” (<xref rid="f0015" ref-type="fig">Figure 3</xref>A), “Neoantigen with mutation” (<xref rid="f0015" ref-type="fig">Figure 3</xref>B), “Neoantigen with clinical information” (<xref rid="f0015" ref-type="fig">Figure 3</xref>C), and “Detailed neoantigen” (<xref rid="f0015" ref-type="fig">Figure 3</xref>D), are displayed. In “Tumor type”, three parts, including the “Statistics” (<xref rid="f0015" ref-type="fig">Figure 3</xref>E), “Neoantigen with clinical information” (<xref rid="f0015" ref-type="fig">Figure 3</xref>F), and “Detailed neoantigen” (<xref rid="f0015" ref-type="fig">Figure 3</xref>G), are displayed. In the “Shared neoantigens”, the distribution of shared neoantigens that occur in at least two tumor samples is displayed. The table below the boxplot displays the shared neoantigens that meet different thresholds. The genes and mutations are linked to CandrisDB <xref rid="b0085" ref-type="bibr">[17]</xref> to check whether they are driver genes or driver mutations since shared neoantigens derived from driver mutations would be potential ideal targets for tumor immunotherapy (<xref rid="f0015" ref-type="fig">Figure 3</xref>H).<fig id="f0015"><label>Figure 3</label><caption><p><bold>Screenshots of the “Browse” page of TSNAdb v2.0</bold></p><p><bold>A.</bold> The “Statistics” part of the “Mutation type” page. <bold>B.</bold> The “Neoantigen with mutation” part of the “Mutation type” page. <bold>C.</bold> The “Neoantigen with clinical information” part of the “Mutation type” page. <bold>D.</bold> The “Detailed neoantigen” part of the “Mutation type” page. <bold>E.</bold> The “Statistics” part of the “Tumor type” page. <bold>F.</bold> The “Neoantigen with mutation” part of the “Tumor type” page. <bold>G.</bold> The “Detailed neoantigen” part of the “Tumor type” page. <bold>H.</bold> The “Shared neoantigens” page.</p></caption><graphic xlink:href="gr3"/></fig></p>
      <p id="p0055">The “Search” page contains the main page and two subpages “Gene” and “HLA”. On the main page of “Search”, users could search for desired neoantigens by selecting the mutation type, tumor type, and gene. Compared with the “Detailed neoantigen” of the “Browse” page, it could provide more customized functions, such as sorting and searching. In the subpages “Gene” and “HLA”, the detailed neoantigens and their distribution of selected genes or HLAs would be displayed once searching. The displayed pie charts are linked with the bellowed table that the detailed neoantigens would be changed once clicking on the part of the pie charts.</p>
      <p id="p0060">On the “Collected” page, all collected neoantigens are validated by experiments to be presented to the cell surface or immunogenic, which are different from those in TSNAdb v1.0. The corresponding genes and mutations of neoantigens are linked to CandrisDB as those in the “Shared neoantigens”.</p>
    </sec>
  </sec>
  <sec id="s0045">
    <title>Discussion and perspectives</title>
    <p id="p0065">Neoantigens play an important role in tumor immunotherapy. A comprehensive and high-confidence neoantigen database would greatly meet the needs of clinical research. In TSNAdb v2.0, we predict more mutation type-derived neoantigens with stricter criteria, present the tissue-specific and gene-specific distribution of candidate tumor-specific neoantigens of TCGA tumor samples, and collect 1856 neoantigens that have been experimentally validated, which is the most systematic database of tumor-specific neoantigens at present. Compared with other databases, TSNAdb v2.0 has several advantages as follows. First, TSNAdb v2.0 provides both high-quality predicted neoantigens and experimentally validated neoantigens, while most of the other databases except NEPdb only provide one of them. Compared with NEPdb, TSNAdb v2.0 provides more sources of predicted neoantigens and has richer forms of presentation. Second, TSNAdb v2.0 provides the analysis of shared neoantigens and links corresponding genes and mutations to CandrisDB to identify high-quality neoantigens, which other databases do not provide. Finally, TNSAdb will be updated continuously to provide constant service for related researchers and clinicians. We believe that it would certainly contribute to neoantigen-based tumor immunotherapy.</p>
    <p id="p0070">However, neoantigens are derived not only from SNVs, INDELs, and Fusions but also from splice variants <xref rid="b0075" ref-type="bibr">[15]</xref>, the mitochondrial genome <xref rid="b0080" ref-type="bibr">[16]</xref>, and translated unannotated open reading frames <xref rid="b0125" ref-type="bibr">[25]</xref>. It is necessary to predict all sources of neoantigens to construct a comprehensive neoantigen database. Limited by the difficulty of collecting other mutations and corresponding HLAs, we only chose three sources of neoantigen in this version of the database. In the following update of TNSAdb, we would add neoantigens from more sources and collect more validated neoantigens to construct a more comprehensive neoantigen database.</p>
  </sec>
  <sec sec-type="data-availability" id="s0050">
    <title>Data availability</title>
    <p id="p0075">TSNAdb v2.0 is freely available at <ext-link ext-link-type="uri" xlink:href="https://pgx.zju.edu.cn/tsnadb/" id="ir015">https://pgx.zju.edu.cn/tsnadb/</ext-link>.</p>
  </sec>
  <sec sec-type="COI-statement" id="s0055">
    <title>Competing interests</title>
    <p id="p0080">The authors have declared no competing interests.</p>
  </sec>
  <sec id="s0060">
    <title>CRediT authorship contribution statement</title>
    <p id="p0085"><bold>Jingcheng Wu:</bold> Methodology, Formal analysis, Writing – original draft, Visualization. <bold>Wenfan Chen:</bold> Formal analysis, Investigation. <bold>Yuxuan Zhou:</bold> Data curation, Investigation. <bold>Ying Chi:</bold> Methodology, Resources. <bold>Xiansheng Hua:</bold> Resources. <bold>Jian Wu:</bold> Methodology. <bold>Xun Gu:</bold> Methodology. <bold>Shuqing Chen:</bold> Conceptualization, Resources. <bold>Zhan Zhou:</bold> Conceptualization, Supervision, Writing – review &amp; editing. All authors have read and approved the final manuscript.</p>
  </sec>
</body>
<back>
  <ref-list id="bi005">
    <title>References</title>
    <ref id="b0005">
      <label>1</label>
      <element-citation publication-type="journal" id="h0005">
        <person-group person-group-type="author">
          <name>
            <surname>Zacharakis</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Chinnasamy</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Black</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>Y.C.</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer</article-title>
        <source>Nat Med</source>
        <volume>24</volume>
        <year>2018</year>
        <fpage>724</fpage>
        <lpage>730</lpage>
        <pub-id pub-id-type="pmid">29867227</pub-id>
      </element-citation>
    </ref>
    <ref id="b0010">
      <label>2</label>
      <element-citation publication-type="journal" id="h0010">
        <person-group person-group-type="author">
          <name>
            <surname>Tran</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Robbins</surname>
            <given-names>P.F.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>Y.C.</given-names>
          </name>
          <name>
            <surname>Prickett</surname>
            <given-names>T.D.</given-names>
          </name>
          <name>
            <surname>Gartner</surname>
            <given-names>J.J.</given-names>
          </name>
          <name>
            <surname>Jia</surname>
            <given-names>L.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>T-cell transfer therapy targeting mutant KRAS in cancer</article-title>
        <source>N Engl J Med</source>
        <volume>375</volume>
        <year>2016</year>
        <fpage>2255</fpage>
        <lpage>2262</lpage>
        <pub-id pub-id-type="pmid">27959684</pub-id>
      </element-citation>
    </ref>
    <ref id="b0015">
      <label>3</label>
      <element-citation publication-type="journal" id="h0015">
        <person-group person-group-type="author">
          <name>
            <surname>Keskin</surname>
            <given-names>D.B.</given-names>
          </name>
          <name>
            <surname>Anandappa</surname>
            <given-names>A.J.</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Tirosh</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Mathewson</surname>
            <given-names>N.D.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial</article-title>
        <source>Nature</source>
        <volume>565</volume>
        <year>2019</year>
        <fpage>234</fpage>
        <lpage>239</lpage>
        <pub-id pub-id-type="pmid">30568305</pub-id>
      </element-citation>
    </ref>
    <ref id="b0020">
      <label>4</label>
      <element-citation publication-type="journal" id="h0020">
        <person-group person-group-type="author">
          <name>
            <surname>Hilf</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Kuttruff-Coqui</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Frenzel</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Bukur</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Stevanović</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Gouttefangeas</surname>
            <given-names>C.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Actively personalized vaccination trial for newly diagnosed glioblastoma</article-title>
        <source>Nature</source>
        <volume>565</volume>
        <year>2019</year>
        <fpage>240</fpage>
        <lpage>245</lpage>
        <pub-id pub-id-type="pmid">30568303</pub-id>
      </element-citation>
    </ref>
    <ref id="b0025">
      <label>5</label>
      <element-citation publication-type="journal" id="h0025">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>DeepHLApan: a deep learning approach for neoantigen prediction considering both HLA–peptide binding and immunogenicity</article-title>
        <source>Front Immunol</source>
        <volume>10</volume>
        <year>2019</year>
        <fpage>2559</fpage>
        <pub-id pub-id-type="pmid">31736974</pub-id>
      </element-citation>
    </ref>
    <ref id="b0030">
      <label>6</label>
      <element-citation publication-type="journal" id="h0030">
        <person-group person-group-type="author">
          <name>
            <surname>O’Donnell</surname>
            <given-names>T.J.</given-names>
          </name>
          <name>
            <surname>Rubinsteyn</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Laserson</surname>
            <given-names>U.</given-names>
          </name>
        </person-group>
        <article-title>MHCflurry 2.0: improved pan-allele prediction of MHC class I-presented peptides by incorporating antigen processing</article-title>
        <source>Cell Syst</source>
        <volume>11</volume>
        <year>2020</year>
        <fpage>42</fpage>
        <lpage>48</lpage>
        <pub-id pub-id-type="pmid">32711842</pub-id>
      </element-citation>
    </ref>
    <ref id="b0035">
      <label>7</label>
      <element-citation publication-type="journal" id="h0035">
        <person-group person-group-type="author">
          <name>
            <surname>Jurtz</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Paul</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Andreatta</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Marcatili</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Peters</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Nielsen</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>NetMHCpan-4.0: improved peptide–MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data</article-title>
        <source>J Immunol</source>
        <volume>199</volume>
        <year>2017</year>
        <fpage>3360</fpage>
        <lpage>3368</lpage>
        <pub-id pub-id-type="pmid">28978689</pub-id>
      </element-citation>
    </ref>
    <ref id="b0040">
      <label>8</label>
      <element-citation publication-type="journal" id="h0040">
        <person-group person-group-type="author">
          <name>
            <surname>Hundal</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Kiwala</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>McMichael</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>C.A.</given-names>
          </name>
          <name>
            <surname>Xia</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Wollam</surname>
            <given-names>A.T.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>pVACtools: a computational toolkit to identify and visualize cancer neoantigens</article-title>
        <source>Cancer Immunol Res</source>
        <volume>8</volume>
        <year>2020</year>
        <fpage>409</fpage>
        <lpage>420</lpage>
        <pub-id pub-id-type="pmid">31907209</pub-id>
      </element-citation>
    </ref>
    <ref id="b0045">
      <label>9</label>
      <element-citation publication-type="journal" id="h0045">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Lyu</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection</article-title>
        <source>R Soc Open Sci</source>
        <volume>4</volume>
        <year>2017</year>
        <fpage>170050</fpage>
        <pub-id pub-id-type="pmid">28484631</pub-id>
      </element-citation>
    </ref>
    <ref id="b0050">
      <label>10</label>
      <element-citation publication-type="journal" id="h0050">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Ren</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>X.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>TSNAD v2.0: a one-stop software solution for tumor-specific neoantigen detection. Comput Struct</article-title>
        <source>Biotechnol J</source>
        <volume>19</volume>
        <year>2021</year>
        <fpage>4510</fpage>
        <lpage>4516</lpage>
      </element-citation>
    </ref>
    <ref id="b0055">
      <label>11</label>
      <element-citation publication-type="journal" id="h0055">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Wei</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>K.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>pTuneos: prioritizing tumor neoantigens from next-generation sequencing data</article-title>
        <source>Genome Med</source>
        <volume>11</volume>
        <year>2019</year>
        <fpage>67</fpage>
        <pub-id pub-id-type="pmid">31666118</pub-id>
      </element-citation>
    </ref>
    <ref id="b0060">
      <label>12</label>
      <element-citation publication-type="journal" id="h0060">
        <person-group person-group-type="author">
          <name>
            <surname>Scholtalbers</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Boegel</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Bukur</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Byl</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Goerges</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Sorn</surname>
            <given-names>P.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression</article-title>
        <source>Genome Med</source>
        <volume>7</volume>
        <year>2015</year>
        <fpage>118</fpage>
        <pub-id pub-id-type="pmid">26589293</pub-id>
      </element-citation>
    </ref>
    <ref id="b0065">
      <label>13</label>
      <element-citation publication-type="journal" id="h0065">
        <person-group person-group-type="author">
          <name>
            <surname>Charoentong</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Finotello</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Angelova</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Mayer</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Efremova</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Rieder</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Pan-cancer immunogenomic analyses reveal genotype–immunophenotype relationships and predictors of response to checkpoint blockade</article-title>
        <source>Cell Rep</source>
        <volume>18</volume>
        <year>2017</year>
        <fpage>248</fpage>
        <lpage>262</lpage>
        <pub-id pub-id-type="pmid">28052254</pub-id>
      </element-citation>
    </ref>
    <ref id="b0070">
      <label>14</label>
      <element-citation publication-type="journal" id="h0070">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Z.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>TSNAdb: a database for tumor-specific neoantigens from immunogenomics data analysis</article-title>
        <source>Genomics Proteomics Bioinformatics</source>
        <volume>16</volume>
        <year>2018</year>
        <fpage>276</fpage>
        <lpage>282</lpage>
        <pub-id pub-id-type="pmid">30223042</pub-id>
      </element-citation>
    </ref>
    <ref id="b0075">
      <label>15</label>
      <element-citation publication-type="journal" id="h0075">
        <person-group person-group-type="author">
          <name>
            <surname>Mishto</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Mansurkhodzhaev</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Ying</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Bitra</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Cordfunke</surname>
            <given-names>R.A.</given-names>
          </name>
          <name>
            <surname>Henze</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>An <italic>in silico</italic>–<italic>in vitro</italic> pipeline identifying an HLA-A*02:01<sup>+</sup> KRAS G12V<sup>+</sup> spliced epitope candidate for a broad tumor-immune response in cancer patients</article-title>
        <source>Front Immunol</source>
        <volume>10</volume>
        <year>2019</year>
        <fpage>2572</fpage>
        <pub-id pub-id-type="pmid">31803176</pub-id>
      </element-citation>
    </ref>
    <ref id="b0080">
      <label>16</label>
      <element-citation publication-type="journal" id="h0080">
        <person-group person-group-type="author">
          <name>
            <surname>Prota</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Lechuga-vieco</surname>
            <given-names>A.V.</given-names>
          </name>
          <name>
            <surname>De Libero</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <article-title>Mitochondrial proteins as source of cancer neoantigens</article-title>
        <source>Int J Mol Sci</source>
        <volume>23</volume>
        <year>2022</year>
        <fpage>2627</fpage>
        <pub-id pub-id-type="pmid">35269772</pub-id>
      </element-citation>
    </ref>
    <ref id="b0085">
      <label>17</label>
      <element-citation publication-type="journal" id="h0085">
        <person-group person-group-type="author">
          <name>
            <surname>Zhao</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Haltom</surname>
            <given-names>J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>CanDriS: posterior profiling of cancer-driving sites based on two-component evolutionary model</article-title>
        <source>Brief Bioinform</source>
        <volume>22</volume>
        <year>2021</year>
        <fpage>bbab131</fpage>
        <pub-id pub-id-type="pmid">33876217</pub-id>
      </element-citation>
    </ref>
    <ref id="b0090">
      <label>18</label>
      <element-citation publication-type="journal" id="h0090">
        <person-group person-group-type="author">
          <name>
            <surname>Zhao</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Z.</given-names>
          </name>
        </person-group>
        <article-title>Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy</article-title>
        <source>Pharmacogenomics</source>
        <volume>21</volume>
        <year>2020</year>
        <fpage>637</fpage>
        <lpage>645</lpage>
        <pub-id pub-id-type="pmid">32423288</pub-id>
      </element-citation>
    </ref>
    <ref id="b0095">
      <label>19</label>
      <element-citation publication-type="journal" id="h0095">
        <person-group person-group-type="author">
          <name>
            <surname>Gao</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Liang</surname>
            <given-names>W.W.</given-names>
          </name>
          <name>
            <surname>Foltz</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>Mutharasu</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Jayasinghe</surname>
            <given-names>R.G.</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Driver fusions and their implications in the development and treatment of human cancers</article-title>
        <source>Cell Rep</source>
        <volume>23</volume>
        <year>2018</year>
        <fpage>227</fpage>
        <lpage>238</lpage>
        <pub-id pub-id-type="pmid">29617662</pub-id>
      </element-citation>
    </ref>
    <ref id="b0100">
      <label>20</label>
      <element-citation publication-type="journal" id="h0100">
        <person-group person-group-type="author">
          <name>
            <surname>Haas</surname>
            <given-names>B.J.</given-names>
          </name>
          <name>
            <surname>Dobin</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Stransky</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Pochet</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Regev</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Accuracy assessment of fusion transcript detection via read-mapping and <italic>de novo</italic> fusion transcript assembly-based methods</article-title>
        <source>Genome Biol</source>
        <volume>20</volume>
        <year>2019</year>
        <fpage>213</fpage>
        <pub-id pub-id-type="pmid">31639029</pub-id>
      </element-citation>
    </ref>
    <ref id="b0105">
      <label>21</label>
      <element-citation publication-type="journal" id="h0105">
        <person-group person-group-type="author">
          <name>
            <surname>Tan</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Jian</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Wan</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>G.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>dbPepNeo: a manually curated database for human tumor neoantigen peptides</article-title>
        <source>Database</source>
        <volume>2020</volume>
        <year>2020</year>
        <fpage>baaa004</fpage>
        <pub-id pub-id-type="pmid">32090262</pub-id>
      </element-citation>
    </ref>
    <ref id="b0110">
      <label>22</label>
      <element-citation publication-type="journal" id="h0110">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>W.J.</given-names>
          </name>
          <name>
            <surname>Qu</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>C.Y.</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Lai</surname>
            <given-names>A.L.</given-names>
          </name>
          <name>
            <surname>Luo</surname>
            <given-names>M.Y.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>NeoPeptide: an immunoinformatic database of T-cell-defined neoantigens</article-title>
        <source>Database</source>
        <volume>2019</volume>
        <year>2019</year>
        <fpage>baz128</fpage>
        <pub-id pub-id-type="pmid">31819989</pub-id>
      </element-citation>
    </ref>
    <ref id="b0115">
      <label>23</label>
      <element-citation publication-type="journal" id="h0115">
        <person-group person-group-type="author">
          <name>
            <surname>Xia</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Bai</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Fan</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>NEPdb: a database of T-cell experimentally-validated neoantigens and pan-cancer predicted neoepitopes for cancer immunotherapy</article-title>
        <source>Front Immunol</source>
        <volume>12</volume>
        <year>2021</year>
        <fpage>644637</fpage>
        <pub-id pub-id-type="pmid">33927717</pub-id>
      </element-citation>
    </ref>
    <ref id="b0120">
      <label>24</label>
      <element-citation publication-type="journal" id="h0120">
        <person-group person-group-type="author">
          <name>
            <surname>Vigneron</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Stroobant</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Van Den Eynde</surname>
            <given-names>B.J.</given-names>
          </name>
          <name>
            <surname>Van Der Bruggen</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>Database of T cell-defined human tumor antigens: the 2013 update</article-title>
        <source>Cancer Immun</source>
        <volume>13</volume>
        <year>2013</year>
        <fpage>15</fpage>
        <pub-id pub-id-type="pmid">23882160</pub-id>
      </element-citation>
    </ref>
    <ref id="b0125">
      <label>25</label>
      <element-citation publication-type="journal" id="h0125">
        <person-group person-group-type="author">
          <name>
            <surname>Ouspenskaia</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Law</surname>
            <given-names>T.E.</given-names>
          </name>
          <name>
            <surname>Clauser</surname>
            <given-names>K.R.</given-names>
          </name>
          <name>
            <surname>Klaeger</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Keskin</surname>
            <given-names>D.B.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>B.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Abstract 566: Neoantigens from translated unannotated open reading frames in cancer</article-title>
        <source>Annual Meeting of the American-Association-for-Cancer-Research</source>
        <volume>79</volume>
        <year>2019</year>
        <fpage>566</fpage>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="s0070" sec-type="supplementary-material">
    <title>Supplementary material</title>
    <p id="p0100">The following are the Supplementary material to this article:<supplementary-material content-type="local-data" id="m0005"><caption><title>Supplementary Table S1</title><p><bold>The detailed information of neoantigens shared in at least two samples</bold></p></caption><media xlink:href="mmc1.xlsx"/></supplementary-material></p>
  </sec>
  <ack id="ak005">
    <title>Acknowledgments</title>
    <p id="p0090">This work was supported by the <funding-source id="gp005"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> (Grant Nos. 31971371 and U20A20409), the <funding-source id="gp010">Key R&amp;D Program of Zhejiang Province, China</funding-source> (Grant No. 2020C03010), the <funding-source id="gp015">Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China</funding-source> (Grant No. LHDMZ22H300002), and the <funding-source id="gp020">Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare</funding-source>. We thank the Information Technology Center, State Key Lab of CAD&amp;CG, and Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, and also Alibaba Cloud for the support of computing resources. We also gratefully acknowledge Prof. Feng Zhu from Zhejiang University for the critical reading of the manuscript, the TCGA Research Network for referencing the TCGA datasets, and the TCIA for referencing HLA-type data of TCGA samples.</p>
  </ack>
  <fn-group>
    <fn id="d35e918">
      <p id="np005">Peer review under responsibility of Beijing Institute of Genomics, Chinese Academy of Sciences / China National Center for Bioinformation and Genetics Society of China.</p>
    </fn>
    <fn id="s0065" fn-type="supplementary-material">
      <p id="p0095">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.gpb.2022.09.012" id="ir020">https://doi.org/10.1016/j.gpb.2022.09.012</ext-link>.</p>
    </fn>
  </fn-group>
</back>
